Thanks a lot.
And just to reiterate, this is a cash runway that will allow us to reach the end of the year and also the main milestones of our clinical programs.
The ongoing clinical programs, starting with AML, are the ADVANCE II trial, which is in long-term follow-up. Again, the patients are doing well. We're very happy with that outcome. Obviously, the AMLM22-CADENCE trial I just described, in combination with oral Azacitidine, is recruiting as we speak; and the DIVA trial, which is in the new first-line treatment setting of Venetoclax plus Azacitidine, is expected to start mid-this year. So we are in full preparation mode now. Also, together with Olivia Newton-John Cancer Research Institute, we aim to have that trial start in a timely way. Combined, the data from these trials and also, of course, keeping a close eye on how the first line landscape in AML will evolve will allow us to set out a registration trial strategy to get this product to market. And very importantly, of course, right now we are positioning the product in the broadest possible way to address patients that have accomplished first complete remission in AML.
The CML program started with the VITAL-CML trial. It's a trial that addresses patients with a suboptimal response to the current standard of care, specifically tyrosine kinase inhibitors. But also importantly, we have already prepared for, or are in full preparation mode for, a Phase 2 trial that can start as soon as we have the initial safety data from the Phase 1 trial and actually in parallel. So we also wish to start this trial before the year-end. And this trial will specifically address treatment-free remission, which is the ultimate and most important treatment objective in CML, allowing patients to safely stop their TKI usage.
We reported on the ALISON trial, the ovarian cancer trial, at the end of last year.
We had presentations at Asco. We had a two-year survival follow-up end of last year. It delivered what it needed to deliver, which was safety and feasibility in this indication.
However, ovarian cancer is a quite complex disease.
So we think that specifically in relation to the tumor microenvironment which is inherent to this disease, we will need to combine it with other therapeutic modalities. And also with respect to the focus of the company. We have decided to focus on the broader myeloid blood cancer space because it allows us to be very competitive there, in contrast to ovarian cancer.
The ovarian cancer competitive landscape is different. And also from the company's perspective, the myeloid blood cancers from now on will be the main focus.
But nevertheless, the ovarian cancer program has been successful and we are looking to partner it or to combine it with other therapeutic modalities.
Now, to start with the primary concern in AML, and also later explaining how it relates to CML.
The only concern in AML is survival. It's such a deadly disease that the first and most important thing is to get it under control. Most patients, unfortunately, relapse and pass away. Despite initial treatment, the survival rate of AML is still 25% or less. With current standard of care.
Today, the only curative approach is hematopoietic stem cell transplant.
And that's a dangerous procedure which many patients cannot undergo. So the only objective in AML is to make sure patients are able to survive.
And what we have done as part of giving patients a bigger platform on our website, we have taken a few patient interviews.
This patient called Jacob has taken part in our ADVANCE II trial.
And the long story short is the extra life that he experiences now from day to day has allowed him to also see the birth of his grandchild. So this is AML.
And with respect to the treatment landscape in AML, there has been for 30-40 years really no change.
It's always been high-intensity chemotherapy, which is available for roughly half of the patients. Other half of the patients are considered not fit enough to undergo this intensive chemotherapy. So for the unfit patients, which are patients 75 years and older, or patients that have comorbidities and for which the high intensity chemotherapy is not available, there's now a new drug called venetoclax, which is combined with an injectable form of azacitidine.
This first line treatment landscape is shifting, and the reason is that Venetoclax is so successful that it's now also being tested more and more in Fit patients as an alternative to high intensity chemotherapy. And the first randomized controlled data were also presented end of last year at ASH. And what we have seen is that the patients that were treated with venetoclax and azacitidine had a better performance, specifically in the first year as compared to patients treated with high intensity chemotherapy. So we expect a bigger shift towards venetoclax and azacitidine in the AML landscape.
And we have adjusted our clinical trial strategy accordingly.
In CML, the situation is very different. In CML, the overall survival is very similar to the general population. However, it requires day-to-day targeted treatment of the disease, which is in the form of tyrosine kinase inhibitors or TKIs.
The TKIs suppress the disease. But what is very much overlooked is the effect of the TKIs on the quality of life of patients.
And these are just two of the interviews that are on our website. The gentleman Giora Sharf is part of a patient organization who really encouraged us to continue and to be part of innovation in CML. And also the young lady called Solveig, who was also in our annual report, indicates how badly the TKIs are affecting her quality of life and how badly she would also like to have a chance of reaching treatment-free remission. So this is in a nutshell, why we do it.
The most important part of it is that the immune system, in the end, is also in CML considered to be the key to potential long-term survival without being dependent on tyrosine kinase inhibitors. There is renewed interest in the CML space since the discovery of a new class of TKIs. The TKIs, starting with Gleevec, are already 20 years old in the treatment of CML. They have been developed into second-generation TKIs, but more recently, third-generation TKIs have been developed that have a slightly different mode of action that is more specific for the driver mutation of CML called BCR-ABL, and Novartis, which was the first company to enter the CML space with its TKI called Gleevec, has now also been the first to introduce a new class of TKIs, called allosteric inhibitors, into this space.
And they have shown two things. First of all, there is still significant innovation possible in CML, and secondly, it's a very big market that has also resulted in their case in projected peak sales for this product called Asciminib of 4 billion USD. So not surprising. Another compound developed by a company called Terns is now in the hands of another big pharma company called Merck. So Merck is now helping to develop their compound, which is also an allosteric inhibitor, to ultimately challenge the market.
So there was a lot of new attention for the CML field. The relevance for us is that these new TKIs that will have deeper and better responses in CML will allow more and more patients to achieve the optimal goal of treatment-free remission, because this state requires a couple of years of continuous deep response. A very deep response on TKIs before you are allowed to stop your TKIs. And when you stop, that's when the disease comes back.
And this is where we, with Vididencel, will aim to improve TFR success.
So actually, we are dovetailing on the success of these new classes of TKIs and more and more patients reaching these deep molecular responses.
So, how do we expand the indication to CML? To expand the indication to CML, you have to start with the Phase 1 trial and show, of course, safety and tolerability. But also, what we have already done is we focus on patients with suboptimal responses to TKI, so that we have embedded in the trial the possibility to observe what happens at the disease level, which is what you call early molecular responses. So all those data will start accumulating since the start of the trial. And we will hope to have the first eight patients already treated to the point that we can have a readout in the second half of the year if the safety is confirmed. We have so far not seen any safety-related issues with our product in the clinical trials, but of course, we need to establish it now in CML.
Then we can also start the phase two trial. The phase two trial will focus on patients with a second TFR attempt. It means that they have already failed an earlier TFR attempt, meaning that the disease levels were going up and they had to be restarted on either their existing or new TKI. But if they again reach these very deep remissions and they can do a second TFR attempt, the failure rate is even higher. In the first TFR attempt, it's typically 50% that patients fail within the first 6 to 12 months.
In the second TFR attempt, it's typically 75%. So we'll have a good chance of success. Also, in that setting, picking up signals of efficacy relatively early. So this is how the CML trial is now set up.
And of course, we're very happy that the VITAL-CML trial is actually ongoing as we speak. So to wrap it up, we have an ambitious clinical development plan that we communicated end of last year. Very importantly, it aligns with the evolving first line treatment landscape in AML, and it will allow us to position Vididencel broadly as a first line post-remission therapy in AML, meaning across all AML subtypes.
We are with our immunotherapy approach, not dependent on individual mutations. Also, we will make it independent of the measurable residual disease status, because also patients that have undetectable levels of disease have a high risk of relapse.
So already in the cadence trial we are capturing the full spectrum of patients, including patients with undetectable MRD levels. And also we will be after the DIVA trial in a position to combine Vididencel with both high intensity and low intensity first line treatment, being Venetoclax and azacitidine. So we'll basically capture all of the AML patients that successfully achieve a complete remission that will inform our path to market.
And we believe that that will be a much more optimal path to market as compared to only one subgroup of patients that we had originally planned for earlier last year.
Then the indication and expansion to CML is now in effect. Trials. Trials are ongoing. And the VITAL-CML trial has already recruited the first patients, which positions us for an initial readout already in the second half of 2026, which will then also support the start of the phase two trial.
So with that, I'm very excited to report back on the first quarter and happy to take any questions from the audience.
Thank you.